CL2008002726A1 - Compuestos derivados de isoquinolinilo e isoindolinilo, antagonistas de histamina-3; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos del sistema nervioso c - Google Patents
Compuestos derivados de isoquinolinilo e isoindolinilo, antagonistas de histamina-3; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos del sistema nervioso cInfo
- Publication number
- CL2008002726A1 CL2008002726A1 CL200802726A CL2008002726A CL2008002726A1 CL 2008002726 A1 CL2008002726 A1 CL 2008002726A1 CL 200802726 A CL200802726 A CL 200802726A CL 2008002726 A CL2008002726 A CL 2008002726A CL 2008002726 A1 CL2008002726 A1 CL 2008002726A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- isoquinolinilo
- isoindolinilo
- histamina
- antagonistas
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 3
- 210000000653 nervous system Anatomy 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99363607P | 2007-09-12 | 2007-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008002726A1 true CL2008002726A1 (es) | 2008-10-10 |
Family
ID=40261509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200802726A CL2008002726A1 (es) | 2007-09-12 | 2008-09-12 | Compuestos derivados de isoquinolinilo e isoindolinilo, antagonistas de histamina-3; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos del sistema nervioso c |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20090069300A1 (enExample) |
| EP (1) | EP2200989A1 (enExample) |
| JP (1) | JP2010539180A (enExample) |
| KR (1) | KR20100054856A (enExample) |
| CN (1) | CN101848896A (enExample) |
| AP (1) | AP2010005202A0 (enExample) |
| AR (1) | AR068423A1 (enExample) |
| AU (1) | AU2008298926A1 (enExample) |
| BR (1) | BRPI0817061A2 (enExample) |
| CA (1) | CA2699384A1 (enExample) |
| CL (1) | CL2008002726A1 (enExample) |
| CO (1) | CO6300955A2 (enExample) |
| CR (1) | CR11303A (enExample) |
| DO (1) | DOP2010000079A (enExample) |
| EA (1) | EA201000316A1 (enExample) |
| EC (1) | ECSP10010025A (enExample) |
| MA (1) | MA31699B1 (enExample) |
| MX (1) | MX2010002760A (enExample) |
| NI (1) | NI201000036A (enExample) |
| PA (1) | PA8795701A1 (enExample) |
| PE (1) | PE20090651A1 (enExample) |
| TN (1) | TN2010000105A1 (enExample) |
| TW (1) | TW200927114A (enExample) |
| WO (1) | WO2009036144A1 (enExample) |
| ZA (1) | ZA201001751B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200823204A (en) * | 2006-10-17 | 2008-06-01 | Arena Pharm Inc | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
| GB0907284D0 (en) | 2009-04-28 | 2009-06-10 | Queen Mary & Westfield College | Compounds for inducing cellular apoptosis |
| HUE034911T2 (hu) | 2009-07-27 | 2018-03-28 | Gilead Sciences Inc | Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| US20130203756A1 (en) * | 2010-10-29 | 2013-08-08 | Jamie L. Bunda | Isoindoline pde10 inhibitors |
| WO2012154760A1 (en) * | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| BR112014000267A2 (pt) | 2011-07-04 | 2016-09-20 | Bayer Ip Gmbh | utilização de isoquinolinonas, isoquinolinedionas, isoquinolinetrionas e dihidroisoquinolinonas substituídas ou, em cada caso, sais das mesmas como agentes ativos contra o stress abiótico em plantas |
| WO2013076590A1 (en) | 2011-11-23 | 2013-05-30 | Oxygen Healthcare Research Pvt. Ltd | Benzothiazine compounds as h3 receptor ligands |
| CN105254554B (zh) * | 2014-07-14 | 2018-01-30 | 南开大学 | 一种制备异吲哚啉酮类化合物的方法 |
| CA3174353A1 (en) * | 2020-04-08 | 2021-10-14 | Dominic Reynolds | Compounds and methods for modulating splicing |
| CA3191279A1 (en) * | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| US12496297B1 (en) * | 2020-10-23 | 2025-12-16 | Washington University | Compositions of autophagy modulating agents and uses thereof |
| CN115819347B (zh) * | 2022-11-14 | 2024-08-30 | 暨明医药科技（苏州）有限公司 | 一种1-烷基-3-溴吡唑的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3933829A (en) * | 1974-08-22 | 1976-01-20 | John Wyeth & Brother Limited | 4-Aminoquinoline derivatives |
| US4166853A (en) * | 1978-05-05 | 1979-09-04 | The Upjohn Company | Antihypertensive 7-trifluoromethyl-4-aminoquinolones |
| US4159331A (en) * | 1978-05-05 | 1979-06-26 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| ATE253359T1 (de) * | 1997-05-01 | 2003-11-15 | Lilly Co Eli | Antithrombotische mittel |
| JP2004532834A (ja) | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
| PT2208727E (pt) * | 2002-09-19 | 2012-10-11 | Lilly Co Eli | Éteres diarílicos como antagonista do receptor opióide |
| KR101792651B1 (ko) * | 2004-05-14 | 2017-11-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물 |
| US20060014733A1 (en) * | 2004-07-19 | 2006-01-19 | Pfizer Inc | Histamine-3 agonists and antagonists |
| US7381732B2 (en) * | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| EP1848696A1 (en) * | 2005-01-21 | 2007-10-31 | Schering Corporation | Imidazole and benzimidazole derivates useful as histamine h3 antagonists |
| US20070032475A1 (en) * | 2005-04-15 | 2007-02-08 | Ye Xiaocong M | Novel compounds useful for bradykinin B1 receptor antagonism |
-
2008
- 2008-09-11 US US12/208,794 patent/US20090069300A1/en not_active Abandoned
- 2008-09-11 KR KR1020107007943A patent/KR20100054856A/ko not_active Ceased
- 2008-09-11 MX MX2010002760A patent/MX2010002760A/es not_active Application Discontinuation
- 2008-09-11 WO PCT/US2008/075981 patent/WO2009036144A1/en not_active Ceased
- 2008-09-11 EP EP08799453A patent/EP2200989A1/en not_active Withdrawn
- 2008-09-11 JP JP2010524978A patent/JP2010539180A/ja not_active Withdrawn
- 2008-09-11 AU AU2008298926A patent/AU2008298926A1/en not_active Abandoned
- 2008-09-11 CN CN200880106892A patent/CN101848896A/zh active Pending
- 2008-09-11 CA CA2699384A patent/CA2699384A1/en not_active Abandoned
- 2008-09-11 AP AP2010005202A patent/AP2010005202A0/xx unknown
- 2008-09-11 BR BRPI0817061 patent/BRPI0817061A2/pt not_active Application Discontinuation
- 2008-09-11 EA EA201000316A patent/EA201000316A1/ru unknown
- 2008-09-12 TW TW097135281A patent/TW200927114A/zh unknown
- 2008-09-12 AR ARP080103964A patent/AR068423A1/es not_active Application Discontinuation
- 2008-09-12 PE PE2008001597A patent/PE20090651A1/es not_active Application Discontinuation
- 2008-09-12 PA PA20088795701A patent/PA8795701A1/es unknown
- 2008-09-12 CL CL200802726A patent/CL2008002726A1/es unknown
-
2010
- 2010-03-04 CR CR11303A patent/CR11303A/es not_active Application Discontinuation
- 2010-03-05 TN TNP2010000105A patent/TN2010000105A1/fr unknown
- 2010-03-10 EC EC2010010025A patent/ECSP10010025A/es unknown
- 2010-03-11 NI NI201000036A patent/NI201000036A/es unknown
- 2010-03-11 DO DO2010000079A patent/DOP2010000079A/es unknown
- 2010-03-11 ZA ZA2010/01751A patent/ZA201001751B/en unknown
- 2010-03-12 MA MA32688A patent/MA31699B1/fr unknown
- 2010-03-15 CO CO10030398A patent/CO6300955A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0817061A2 (pt) | 2015-03-24 |
| WO2009036144A1 (en) | 2009-03-19 |
| AR068423A1 (es) | 2009-11-18 |
| AP2010005202A0 (en) | 2010-04-30 |
| JP2010539180A (ja) | 2010-12-16 |
| EP2200989A1 (en) | 2010-06-30 |
| AU2008298926A1 (en) | 2009-03-19 |
| DOP2010000079A (es) | 2010-03-31 |
| PA8795701A1 (es) | 2009-04-23 |
| ECSP10010025A (es) | 2010-08-31 |
| US20090069300A1 (en) | 2009-03-12 |
| TN2010000105A1 (fr) | 2011-09-26 |
| ZA201001751B (en) | 2010-11-24 |
| MX2010002760A (es) | 2010-04-01 |
| MA31699B1 (fr) | 2010-09-01 |
| PE20090651A1 (es) | 2009-05-28 |
| TW200927114A (en) | 2009-07-01 |
| CO6300955A2 (es) | 2011-07-21 |
| CN101848896A (zh) | 2010-09-29 |
| EA201000316A1 (ru) | 2010-10-29 |
| KR20100054856A (ko) | 2010-05-25 |
| NI201000036A (es) | 2010-08-13 |
| CA2699384A1 (en) | 2009-03-19 |
| CR11303A (es) | 2010-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008000703A1 (es) | Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos. | |
| CL2008000496A1 (es) | Compuestos derivados de purina; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades infecciosas, cancer, alergias y otras afecciones inflamatorias. | |
| CL2008000887A1 (es) | Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de | |
| CL2008000197A1 (es) | Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
| CL2007002971A1 (es) | Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras. | |
| CL2007003804A1 (es) | Compuestos derivados de indazol; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar condiciones inflamatorias, tales como asma, epoc. | |
| CL2008000793A1 (es) | Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro. | |
| CL2008000029A1 (es) | Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
| CL2014000311A1 (es) | Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio. | |
| CL2007001882A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| CL2008000467A1 (es) | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma | |
| CL2013001713A1 (es) | Compuestos derivados de bemzimidazol, proceso para prepar dichos compuestos; composicion farmaceutica que los comprende; proceso para preparar esta composicion farmaceutica; y su uso para inhibir la replicacion del visus sincicial respiratorio (rsv). | |
| CL2007002107A1 (es) | Compuestos derivados de bencil piperidin-1-il amina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, ateroesclerosis, vasculopatia periferica, dislipidemia, entre otras enfermedades. | |
| CL2007003212A1 (es) | Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer. | |
| CL2012003643A1 (es) | Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. | |
| CL2007001881A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
| CL2008002319A1 (es) | Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
| BRPI1009781A2 (pt) | compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos | |
| CL2008000794A1 (es) | Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro. | |
| CL2007003423A1 (es) | Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda | |
| CL2007002021A1 (es) | Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias. | |
| CL2007002970A1 (es) | Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras. | |
| CL2007002791A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica que comprende a estos compuestos; combinacion farmaceutica que comprende a estos compuestos; y su uso para tratar trastornos, enfermedades y afecciones seleccionadas de asma, broncoconstri | |
| CL2008000641A1 (es) | Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme |